Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07386054Not yet recruiting
Randomised trial (2 arms), sponsored by Yonsei University. Primary endpoint: Total dose of midazolam administered to achieve OAA/S <= 3 at 30 months. Planned start Feb 2026; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07386054.